AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal

AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner.

from Reuters: Health News https://ift.tt/2FIBT4V
via IFTTT